Diabetic Retinopathy
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study in a Chinese population with diabetic retinopathy.
|
23562823 |
2013 |
Parkinson Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's disease among Taiwanese.
|
20302855 |
2010 |
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
|
17085005 |
2007 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Overexpression of UCHL3 renders breast cancer cells resistant to radiation and chemotherapy, while depletion of UCHL3 sensitizes cells to these treatments, suggesting a determinant role of UCHL3 in cancer therapy.
|
27941124 |
2016 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> experiments were also conducted to confirm the effect of UCHL3 and FOXM1 depletion on tumor growth in nude mouse xenograft models.
|
31598398 |
2019 |
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our study established the UCHL3-FOXM1 axis as a pivotal driver of pancreatic cancer progression and gemcitabine resistance and provided evidence for the potential therapeutic benefit of targeting the UCHL3-FOXM1 axis for pancreatic cancer treatment.
|
31598398 |
2019 |
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our study established the UCHL3-FOXM1 axis as a pivotal driver of pancreatic cancer progression and gemcitabine resistance and provided evidence for the potential therapeutic benefit of targeting the UCHL3-FOXM1 axis for pancreatic cancer treatment.
|
31598398 |
2019 |
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway.
|
31477831 |
2020 |
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway.
|
31477831 |
2020 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Overexpression of UCHL3 renders breast cancer cells resistant to radiation and chemotherapy, while depletion of UCHL3 sensitizes cells to these treatments, suggesting a determinant role of UCHL3 in cancer therapy.
|
27941124 |
2016 |
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, UCHL3 overexpression can render cancer cells resistant to DNA damage inducing chemo and radiotherapy, and targeting UCHL3 can sensitize TNBC to radiation and chemotherapy.
|
31113933 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway.
|
31477831 |
2020 |
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, UCHL3 overexpression can render cancer cells resistant to DNA damage inducing chemo and radiotherapy, and targeting UCHL3 can sensitize TNBC to radiation and chemotherapy.
|
31113933 |
2019 |
Parkinson Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Yet UCHL-3 expression was reduced in the cerebral cortex of PD and DLB patients.
|
16380264 |
2006 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of UCHL3 renders breast cancer cells resistant to radiation and chemotherapy, while depletion of UCHL3 sensitizes cells to these treatments, suggesting a determinant role of UCHL3 in cancer therapy.
|
27941124 |
2016 |
Uterine Cervical Neoplasm
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines.
|
16402389 |
2006 |
Rhabdomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TDP1 overexpression in the topoisomerase therapy-resistant rhabdomyosarcoma is driven by UCHL3 overexpression.
|
29898404 |
2018 |
Ataxia, Spinocerebellar
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, UCHL3 is downregulated in spinocerebellar ataxia with axonal neuropathy (SCAN1), causing elevated levels of TDP1 ubiquitylation and faster turnover rate.
|
29898404 |
2018 |
Childhood Rhabdomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TDP1 overexpression in the topoisomerase therapy-resistant rhabdomyosarcoma is driven by UCHL3 overexpression.
|
29898404 |
2018 |
Axonal neuropathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, UCHL3 is downregulated in spinocerebellar ataxia with axonal neuropathy (SCAN1), causing elevated levels of TDP1 ubiquitylation and faster turnover rate.
|
29898404 |
2018 |
Adult Rhabdomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TDP1 overexpression in the topoisomerase therapy-resistant rhabdomyosarcoma is driven by UCHL3 overexpression.
|
29898404 |
2018 |
Neurodegenerative Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Although the level of UCH-L3 protein in several neurodegenerative diseases is unchanged, we show that in vitro oxidation of recombinant UCH-L3 impairs its deubiquitinating activity.
|
21762696 |
2011 |
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of UCHL3 renders breast cancer cells resistant to radiation and chemotherapy, while depletion of UCHL3 sensitizes cells to these treatments, suggesting a determinant role of UCHL3 in cancer therapy.
|
27941124 |
2016 |
Lewy Body Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Yet UCHL-3 expression was reduced in the cerebral cortex of PD and DLB patients.
|
16380264 |
2006 |
SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, UCHL3 is downregulated in spinocerebellar ataxia with axonal neuropathy (SCAN1), causing elevated levels of TDP1 ubiquitylation and faster turnover rate.
|
29898404 |
2018 |